BACKGROUND: Recently, it was reported that the soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) is secreted by microvascular endothelial cells from human BPH (HPECs). The purpose of this study was to investigate the modulation of sVEGFR-2 by common endothelial cell stimulators. In addition, the physiological role of sVEGFR-2 with regard to the VEGF-stimulated proliferation of HPEC was investigated.
Introduction
Endothelium, the thin layer of cells between the blood stream and the adjacent tissue, is not only a barrier, but it also influences the regulation of organ functions and tumor growth, respectively. Recent studies suggest that endothelium has an important role in the regulation of normal and malignant tumor growth. [1] [2] [3] However, under physiological as well as pathological conditions, the function of microvascular endothelial cells is adapted to the respective organ and tissue. [4] [5] [6] [7] Therefore, it is important to investigate the organ-specific function of the respective endothelium.
Consequently, to get more precise knowledge about the function of endothelial cells in the prostate, it is necessary to analyze endothelial cells of prostate origin. Recently, the isolation and culture of microvascular endothelial cells derived from tissue of human BPH (HPECs) was reported. [7] [8] [9] Furthermore, for the first time we reported that HPECs secrete the soluble vascular endothelial growth factor receptor-2 (sVEGFR-2). 9 Prostatic endothelial cells secrete paracrine factors that contribute to the growth of prostate epithelial and stromal cells. 2, 10, 11 In this connection, the VEGF and its soluble receptors have a central role in regulation of angiogenesis of tumor tissue. 12, 13 VEGF stimulates endothelial cells as well as prostate epithelial cells. Therefore, a modification of the VEGF effect on prostate tumor growth by sVEGFR-2 is supposable. 14 In addition, recent studies characterized sVEGFR-2 as an endogenous inhibitor of lymphangiogenesis. 15 Recently, we observed that sVEGFR-2 secreted by HPEC binds to VEGF. 9 Furthermore, we showed that sVEGFR-2 secretion is modified by VEGF and tumor necrosis factor (TNF)-a.
Thus, the present study targeted the investigation of sVEGFR-2 and the modulation of its secretion from HPECs by several endothelial cell stimulators, which are well-known angiogenic effectors, adenosine triphosphate (ATP), interleukin (IL)-6, IL-8 and IL- 12 . In order to analyze the physiological role of sVEGFR-2, the VEGF-stimulated proliferation of HPECs with and without sVEGFR-2 was investigated. The inhibiting effect of sVEGFR-2 on the VEGF-stimulated proliferation of HPECs suggest that sVEGFR-2 functions as an antiangiogenic factor. 3, 15, 16 Materials and methods
Isolation and culture of HPECs
Fresh BPH tissue was obtained from patients undergoing total suprapubic prostatectomy. All patients gave written informed consent concerning the participation in the study. The diagnosis of BPH was confirmed by the review of various histological sections. The isolation and culture of microvascular endothelial cells from human BPH tissue was performed as described by Stachon et al. 7 Briefly, the prostate tissue was cut into cubes of 8 mm 3 and rinsed with phosphate-buffered saline supplemented with 100 000 U l À1 penicillin G and 100 000 mg l À1 Streptomycin (Gibco, Paisley, UK) under sterile conditions. After incubation with 2.4 U ml À1 dispase (Gibco) for 16 h at 4 1C, these cubes were gently squeezed in endothelial growth medium (endothelial cell growth medium MV, supplemented with 5% fetal calf serum (FCS; Promocell, Heidelberg, Germany). The resulting cell suspension was filtered through a 100 mm cell strainer (Becton Dickinson, Heidelberg, Germany) and washed twice with the endothelial growth medium.
Then, the cell suspension was centrifuged for 5 min at 1400 r.p.m. and afterward the obtained cell pellet was resuspended in endothelial growth medium and seeded into a 75 cm 2 culture flask (Becton Dickinson). Subsequently, cells were cultured at 37 1C, 5% CO 2 in a humidified atmosphere. The exchanging of the culture medium was conducted every 2-3 days. At a confluence of at least 90%, cell selection by use of superparamagnetic beads (Dynal, Oslo, Norway) was performed.
Paramagnetic beads were armed with antibodies against human CD31 (Dianova, Hamburg, Germany) according to the manufacturer's protocol. The endothelial growth medium was removed, and the culture was carefully rinsed twice with phosphate-buffered saline for removing all residues of the medium. About five CD31-coated beads per cell, dissolved in 3 ml phosphatebuffered saline per culture flask, were added to the cell culture. Culture flasks were incubated for 20-40 min at 37 1C. During the incubation, the culture flasks were gently shaken four times. Thereafter, the cells were detached with 3 ml trypsin/EDTA (0.25%; Gibco), and the CD31-positive cells were extracted with a magnet (Dynal). The remaining cell suspension was removed. CD31-positive cells were resuspended and selected again. This selection was repeated five times. Finally, CD31-positive cells were resuspended and seeded in a concentration of 1000 cells cm À2 in a 25 cm 2 culture flask (Becton Dickinson) using the endothelial growth medium. During the following period, the CD31-coated beads detached from the cells. At near confluence, cell selection by use of antihuman CD62E-coated beads was performed as follows: immediately before the cells were selected with antihuman CD62E-coated beads, the cell culture was stimulated with 1 ng ml À1 TNF-á (Sigma-Aldrich, Taufkirchen, Germany) for 4 h to induce a higher CD62E expression on the surface of endothelial cells. 17 Thereupon, the cells were incubated with the beads, detached, extracted and washed using the same procedure as mentioned above. The obtained HPEC suspension was cultured for serial propagation in the endothelial growth medium, using 25 cm 2 culture flasks. Generally, in this study, up to five passages were used.
In order to ensure a pure culture of HPECs, we removed every cell culture if there was any suspicion of alteration (that is, contamination with fibroblasts or bacteria). Therefore, the final number of measurements varies between the experiments.
Flow cytometry
HPECs were detached with 2 ml trypsin/EDTA (0.25%). and washed in endothelial cell basal medium supplemented with 5% FCS (Promocell). Afterward, the cells were washed once with CELLWASH (Becton Dickinson), followed by incubation with mouse antibodies (100 mg per 10 6 cells) against CD31 and CD62E for 30 min in the dark at room temperature. For staining with antibody against CD62E, one HPEC fraction was stimulated for 4 h with 1 ng ml À1 TNF-a before detachment of the cells, and another HPEC fraction was not stimulated at all. CD31 antibodies were fluorescein conjugated, so that in this case a direct staining was obtained. Otherwise, the cells burdened with the primary antibody were washed once with CELLWASH (Becton Dickinson), followed by incubation with a secondary, fluorescein-conjugated rabbit anti-mouse antibody (1:10 dilution) for 30 min in the dark at room temperature. In a following step, all cell preparations were washed once with CELLWASH and fixed with 0.5 ml paraformaldehyde (0.1%) (Sigma, Taufkirchen, Germany). To prove the specificity of the staining, isotype control experiments for each primary immunoglobulin G subtype antibody were performed. Finally, the cells were suspended in 0.5 ml CELLWASH (Becton Dickinson) and analyzed with a fluorescenceactivated cell scanner (FACSCalibur, Becton Dickinson).
Stimulation of sVEGFR-2 secretion
The stimulation of sVEGFR-2 secretion by ATP (SigmaAldrich), IL-6 (R&D Systems, Wiesbaden, Germany), IL-8 (R&D Systems) and IL-12 (R&D Systems) was performed as follows: HPECs were seeded in 24 wells (Becton Dickinson) using 1000 ml endothelial growth medium per well. Generally after 48 h, the HPECs were grown to confluence, and the stimulation with ATP (100 nmol ml À1 ), IL-6 (10 ng ml À1 and 100 ng/ml À1 ), IL-8 (10 ng ml À1 and 100 ng/ml
À1
) and IL-12 (100 ng ml
) was conducted. Both at 48 and 96 h of stimulation, 500 ml of the supernatant was removed and the used culture media was harvested and stored at À70 1C until the sVEGFR-2 measurements were performed. Control experiments without any stimulation were similarly performed by using HPECs of the same prostate preparation.
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Measurement of sVEGFR-2 secretion
The sVEGFR-2 concentration in each well was measured by taking a 100 ml aliquot of the supernatant. Measurements were performed by enzyme-linked immunosorbent assay (ELISA) (R&D Systems). Mouse monoclonal antihuman antibody against sVEGFR-2 as well as biotinylated goat polyclonal antihuman antibody against sVEGFR-2 and recombinant human proteins were supplied by R&D Systems. The procedure was determined exactly following the manufacturer's ELISA protocol (R&D Systems). Absorbance was measured at 450 nm (MRX Revelation, Dynex Technologies, Denkendorf, Germany).
Measurement of HPEC proliferation is dependent on VEGF/sVEGFR-2
To demonstrate the VEGF-stimulated HPEC proliferation and its modulation by sVEGFR-2, the HPECs from one prostate were seeded in 24 wells. After 24 h, the medium was totally exchanged for 500 ml of the endothelial growth medium supplemented with 100 ng ml À1 VEGF (R&D Systems) and an abundance of sVEGFR-2 (fivefold amount of substance ¼ 360 ng ml À1 ). Wells containing endothelial growth medium only with 100 ng ml À1 VEGF served as control.
Cell proliferation was assessed using the Alamar Blue method (Biosource, Solingen, Germany). After 70-80% confluence of HPECs, medium was exchanged for 500 ml RPMI without FCS containing 10% Alamar Blue, a nontoxic aqueous dye. After 2-3 h, the redox reaction, in which Alamar Blue is reduced by the cells, was measured in the supernatant by absorbance readings at 545 and 590 nm by a multifunctional microplate reader (fluorometer; FLUOstar Optima, BMG Labtech GmbH, Offenburg, Germany).
Data results are presented as arbitrary units (AUs; fluorescence). For each well, the cell proliferation was measured in duplicate and the mean was considered for statistical analysis. The differences in cellular growth were analyzed using the Student's t-test. In general, Po0.05 was considered statistically significant.
Statistical analysis
Data are presented as mean ± s.e.m. and n represents the number of experiments. Statistical analysis was performed using the Student's t-test. P-values below 0.05 were considered to be statistically significant.
Results
Cell culture Figure 1 shows typical light microscopic pictures of HPECs from the same BPH in culture. Morphology and cell growth of HPECs showed typical characteristics of endothelial cells: adherent growth and an inhibition of cell growth by contact with other endothelial cells. In general, nearly after 7-10 days a confluent monolayer was reached. After the cell cultures reached confluence, no further cell proliferation was observed. Usually, the lifetime of HPECs was greater than 2 months.
Flow cytometry
Cultured HPECs were analyzed by flow cytometry with regard to the presence of endothelial-specific antigens. As shown in Figure 2a , HPECs were positive for CD31. After stimulation with 1 ng ml À1 TNF-a for 4 h, HPECs were also positive for CD62E (Figure 2c ), whereas unstimulated cells were negative (Figure 2b ).
sVEGFR-2 secretion
In order to demonstrate a time-dependent modulation of sVEGFR-2 secretion by HPECs, we examined the effect of ATP, IL-6, IL-8 and IL-12 at periods of 48 and 96 h after stimulation. The sVEGFR-2 secretion was measured at both periods by ELISA. The individual experiments are shown in Figures 3a, b .
In the supernatant of the HPECs stimulated with 100 nmol ml À1 ATP, the mean increase in the sVEGFR-2 concentration after 48 h was 722.1±29.6 pg ml À1 (n ¼ 8). This was significantly higher than the secretion in unstimulated HPECs (568.6±32.29 pg ml
Further, the mean increase in the sVEGFR-2 concentration by ATP remains significant at 96 h (1209± 58.0 pg ml À1 , n ¼ 8) in comparison with unstimulated HPECs (1035 ± 48.16 pg ml À1 , n ¼ 8, Po0.001). Moreover, at 48 h, 100 ng ml À1 IL-12 did not show significant effects on the sVEGFR-2 secretion (556.3 ± 
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pg ml
À1 , n ¼ 16, P ¼ 0.215; control: 621.0± 41.52 pg ml À1 , n ¼ 16). But at 96 h, in the supernatant of the HPEC medium stimulated with IL-12, the mean stimulated increase in the sVEGFR-2 concentration was 1006±40.3 pg ml À1 (n ¼ 16). This was significantly lower than the secretion of sVEGFR-2 in unstimulated HPECs (1097±31.73 pg ml À1 , n ¼ 16, P ¼ 0.008). Furthermore, after 48 h no significant effect of IL-8 or IL-6 on the sVEGFR-2 secretion was observed (IL-8 10 ng ml À1 : 511.9 ± 72.60 pg ml
À1
, n ¼ 16, P ¼ 0.229; IL-8 100 ng ml
: 530.7 ± 77.14 pg ml À1 , n ¼ 16, P ¼ 0.943; IL-6 10 ng ml À1 : 548.5 ± 89.01 pg ml À1 , n ¼ 15, P ¼ 0.557; IL-6 100 ng ml
: 570.9 ± 87.27 pg ml À1 , n ¼ 16, P ¼ 0.142; control: 529.9±77.14 pg ml
, n ¼ 16). However, after 96 h the sVEGFR-2 secretion was significantly decreased when HPECs were stimulated with 10 ng ml À1 of IL-8 (862.4 ± 101 pg ml À1 , n ¼ 16, P ¼ 0.015; control: 926.6±100.7 pg ml À1 , n ¼ 16). A total volume of 100 ng ml À1 IL-8 or IL-6 both at 10 and 100 ng ml À1 had no significant effect on the sVEGFR-2 secretion after 96 h (IL-8 100 ng ml À1 : 896.6 ± 99.19 pg ml
, n ¼ 16, P ¼ 0.406; IL-6 10 ng ml
: 982.3±103.7 pg ml À1 , n ¼ 15, P ¼ 0.950; IL-6 100 ng ml À1 : 966.6 ± 102.3 pg ml
, n ¼ 16, P ¼ 0.174).
Proliferation of HPECs
The effect of sVEGFR-2 on the VEGF-stimulated HPEC proliferation was determined by Alamar Blue assay. A 70-80% confluence of HPECs in the 24-well plate was reached after 72 h. In comparison with culture conditions without sVEGFR-2 (34 790 ± 400 AU, n ¼ 10), the cell proliferation of the VEGF-stimulated HPECs in addition to sVEGFR-2 (33 030 ± 777 AU, n ¼ 8; P ¼ 0.048) was significantly decreased (Figure 4 ).
Discussion
Growing attention has been drawn to the potential role of the endothelium with regard to initiation and progression of prostate tumor growth. The functional heterogeneity and organ specificity of the various endothelial cells is well known. Therefore, studies involving organ-specific endothelial cells are of great interest. Since our first report on a successful primary culture of microvascular endothelial cells (HPECs) from human BPH, HPECs are available for investigations of their specific paracrine function. The specific isolation and characterization of HPECs were extensively described before. 7 As quality control in the present study, we characterized the isolated cells by flow cytometry to ensure that HPECs are pure microvascular endothelial cells, without any significant contamination by other cell types. Therefore, we refrained from an extensive characterization to obtain satisfactory amounts of HPECs to perform our stimulation experiments. The HPECs showed typical endothelial cell growth, cell morphology and surface antigens, such as CD31 and CD62E. 5, 18 CD62E was expressed by endothelial cells only after stimulation by TNF-a (Figure 2c ). This observation is consistent with previous reports. 17 VEGF is one of the most important angiogenesisinducing factors in benign and malignant prostate tumor growth. VEGF is a potent mitogenic stimulator of prostate endothelial and epithelial cells. 1, [19] [20] [21] Furthermore, the predominant angiogenic factor expressed in the normal prostate is VEGF, especially in both stromal and epithelial cells. [22] [23] [24] Moreover, VEGF contributes to tumor growth and progression through promotion of angiogenesis, enhancement of microvascular permeability and reduction of apoptosis. 13, 25 Previously, we demonstrated the effect of VEGF on the secretion of IL-6 and endothelin-1 by HPECs, suggesting a direct regulation of the paracrine activity of HPECs by VEGF. 7, 8 As a major regulator for angiogenesis, VEGF activates a plethora of signaling pathways through two tyrosine kinase receptors VEGFR-1 and VEGFR-2. 26, 27 But the major signaling receptor for VEGF, mediating most of its biological activities in endothelial cells, is VEGFR-2. 28 In this connection, VEGFR-2 is upregulated in tumor vasculature. [29] [30] [31] So far, only few studies evaluated the physiological role of the soluble entity of VEGFR-2, sVEGFR-2. sVEGFR-2 is a 160-kD protein, 32 which binds to VEGF. 16, 33 Nevertheless, the specific impact on the VEGF-mediated activation of endothelial cells is unclear. 34, 35 Recently, for the first time we reported on the secretion of sVEGFR-2 by microvascular endothelial cells derived by human BPH. 9 We also showed that the Regulation of soluble VEGFR-2 A Aweimer et al secretion of sVEGFR-2 is stimulated by the well-known regulators of angiogenesis, VEGF and TNF-a, respectively. Therefore, in the present study we investigated several other well-known endothelial stimulators. For the first time we report on the ATP effect on HPECs. ATP increases the sVEGFR-2 secretion by HPECs. ATP is known to be a strong regulator of vascular tone, mediating this effect in part by the activation of endothelial cells. 36 ATP exhibits antiproliferative effects and is a potent inhibitor of the growth of human prostate tumors. 37, 38 Some of the effects of ATP are mediated via its breakdown product adenosine. 39 Both ATP and adenosine regulate endothelial cell proliferation. 40 Adenosine also stimulates the release of VEGF from endothelial cells via the A 2 receptor. 41 In this connection, further studies are needed to evaluate whether ATP, via adenosine, stimulates the secretion of sVEGFR-2 by an autocrine secretion of VEGF. Therefore, ATP might be involved in the modification of mitogenic activities as suggested before. 39 Furthermore, for the first time we report on the effect of IL-12 on the sVEGFR-2 secretion by microvascular endothelial cells. IL-12 inhibits endothelial cells functions and angiogenesis. 42 Several studies showed that IL-12 decreases tumor growth and metastasis formation. [43] [44] [45] In this connection, some of the effects of IL-12 are mediated via IL-12-stimulated IFN-g secretion by T and natural killer cells. [46] [47] [48] Furthermore, Duda et al.
49
reported on the IL-12-stimulated release of IFN-g also by endothelial cells. In the same study, the authors observed an IL-12-induced decrease of the RNA levels of VEGF in endothelial cells in vitro. 49 In addition, IFN-g, induced by ), Student's t-test was performed without the unavailable pair value in the control group.
Regulation of soluble VEGFR-2 A Aweimer et al IL-12, has been supposed to reduce the secretion of VEGF by tumor cells and endothelial cells. 50 Therefore, the sVEGFR-2 secretion by endothelial cells might not only directly inhibited by IL-12, but also by autocrinesecreted IFNg. Both IL-12 and IFN-g might be potent to curb the sVEGFR-2-increasing effect of VEGF. Other authors suggested that IFN-g is able to decrease VEGFinduced VEGFR-2 expression in endothelial cells. 51 However, as yet to the best of our knowledge there is no study that investigated the effect of IL-12 on the secretion of the soluble entity of VEGFR-2.
In addition, only IL-8 in a concentration of 10 ng ml
À1
and not 100 ng ml À1 had a significant decreasing effect on the sVEGFR-2 secretion. This observation is in accordance with previous studies, which described the phenomenon of a concentration-dependent effect in general, 52, 53 and in particular for IL-8. 54 ,55 IL-8 and its receptors, CXCR1 and CXCR2, have been described on endothelial cells 56, 57 and have been shown to have a role in endothelial cell proliferation. 58 IL-8 is a well-known proangiogenic and proinflammatory chemokines, with an increased expression in benign and malignant prostate tumors. 59, 60 Moreover, studies showed a coexpression of IL-8 and VEGF in a variety of cancers. 61 IL-8 upregulates VEGF mRNA and protein levels in endothelial cells mediated through its cognate receptor CXCR2, and this results in an autocrine activation of VEGFR-2. 62 Others have reported on a VEGF-independent activation of VEGFR-2 in endothelial cells by In contrast to these observations, we found a significant downregulation of sVEGFR-2 by IL-8 in HPECs. Therefore, further studies should be performed to clarify whether the secretion of sVEGFR-2 is regulated independently from the expression of VEGFR-2 on the cell surface.
Moreover, in the present study we investigated the effect of the well-known endothelial cell stimulator IL-6 on the secretion of sVEGFR-2. IL-6 has been shown to be a potent proangiogenic cytokine, as IL-6 participates in angiogenesis during tumor progression. 63 In addition, IL-6 induces release of VEGF from cultured endothelial cells and tumor cells. 64, 65 Furthermore, previously we showed an increasing effect of VEGF on the IL-6 secretion in HPECs. 7 However, contrary to these data, we did not observe any significant effect of IL-6 on the sVEGFR-2 secretion.
Interestingly, we observed that the interleukins IL-8 and IL-12 affect the cells significantly only after 96 h, whereas the stimulation with ATP showed significant effects after 48 h. These observations suggest that the response of endothelial cells to different effectors is time dependent, as reported by others. 66, 67 Therefore, it cannot be excluded that IL-6 influences the sVEGFR-2 secretion beyond 96 h.
Recently, some authors reported on a sVEGFR-2 dependent reduction of pathological angiogenesis. 3, 16, 68 In addition, Albuquerque et al.
15 characterized sVEGFR-2 as an essential endogenous inhibitor of lymphatic vessel growth. Other data suggest a low-affinity binding between sVEGFR-2 and VEGF, so that they concluded that sVEGFR-2 is not able to significantly compete for VEGF with the cellular VEGF receptors. 33 However, it is conceivable that sVEGFR-2 is not a protein that decreases the VEGF effect on endothelial cells by competing with the VEGF membrane receptors, but that sVEGFR-2 is able to prolong and, therefore, in the long run increases the VEGF effect on endothelial cells. This would be the case when VEGF is only temporarily bound to the sVEGFR-2 receptor and again released. In this case, sVEGFR-2 would function as a temporary storage pool for VEGF, and the release of VEGF from sVEGFR-2 would mean a prolonged VEGF effect.
Previously, we described a significant VEGF-stimulated proliferation of HPECs. 7 In an effort to better understand how sVEGFR-2 is influencing endothelial cells, we investigated the effect of sVEGFR-2 on the VEGF-stimulated proliferation of HPECs. In this respect, for the first time we showed that the proliferation of HPECs was significantly inhibited by sVEGFR-2. This result is in accordance to other recent studies, which reported on an antiangiogenic function of sVEGFR-2. 14, 15, 68, 69 These studies demonstrated an inhibition of cell proliferation due to the interaction of VEGF with sVEGFR-2. Corresponding to these studies and regarding to the role of sVEGFR-2, our results corroborate the assumption that sVEGFR-2 functions as an antiangiogenic factor. However, it cannot be excluded that the observed inhibition was induced by direct effect of sVEGFR-2 on HPEC proliferation.
Further, our results show that sVEGFR-2 is able to modify the VEGF effect on the endothelium of BPH, although until now there have not been any clinical study that investigated the effect of sVEGFR-2 on the progression of BPH growth.
Several studies suggest that tumor tissue growing could be inhibited by the interaction of sVEGFR-2 with VEGF. 3, [14] [15] [16] 68, 69 However, the assumption of Ebos et al.
14 that sVEGFR-2 can modify the VEGF effect on prostate tumor cells could lead to a new therapeutic approach of the treatment of malignant prostate tumor growth. Recently, the use of certain angiogenesis inhibitors in prostate cancer is the focus of several ongoing clinical trials; however, the impact on survival has been relatively modest. 70 To which extent sVEGFR-2 is able to inhibit the growth of prostate tumor tissue has to be elucidated by further investigation.
Taken together, the observed significant effects are relatively small but consistent with our previous studies. [7] [8] [9] In this context, it has to be recognized that HPECs are benign cells that are not characterized by abnormal secretion and proliferation like malignant cells. In order to have standardized experimental settings, relatively short observation periods were used. Within these short periods, several cellular processes (that is, activation of receptors, intracellular second messengers and translational processes) were involved until finally we observed an increased or decreased secretion of sVEGFR-2. Therefore, it is thinkable that in the subsequent time periods the modification of the sVEGFR-2 secretion is more pronounced than observed in these experiments and reported before. [7] [8] [9] Furthermore, sVEGFR-2 decreased the proliferation of HPECs for 45% within 72 h. This significant effect results in a 50% lower cell population within 40 days (94.67% 13 ¼ 49.06%), which is a quite strong effect in relation to the slow growing BPH.
In conclusion, in the present paper our results suggest that the sVEGFR-2 secretion in microvascular endothelial cells from prostate tissue is modulated by
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A Aweimer et al several endothelial cell stimulators in a time-dependent manner. Significant effects were observed by stimulation with ATP, IL-12 and partly IL-8 on the secretion rate of sVEGFR-2 by HPECs. Owing to these data, it is likely that the secretion of sVEGFR-2 is involved in modification of the endothelial response to angiogenesis and inflammation. In the present study, we observed no significant effect of IL-6 on the secretion of sVEGFR-2. As standardization was only performed by stringent use of confluent monolayers, these data have to be confirmed in further studies, that is, by standardization on cell counts or protein concentration, respectively. Furthermore, our results for the first time show that sVEGFR-2 inhibits the VEGF-stimulated proliferation of micovascular endothelial cells of human BPH. Further studies are necessary to elucidate the modulation of the VEGF effect on prostate endothelial cells by sVEGFR-2.
